Contraception for women with epilepsy

Epilepsia

Volumn 47, Issue 9, 2006, Pages 1419-1422

  O'Brien, Michael D ^a   Guillebaud, John ^b  

^a GUY S HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antiepileptic drugs; Contraception; Epilepsy; Females; Liver enzyme induction; Women

Indexed keywords

ACETAZOLAMIDE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; DESOGESTREL; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; ETIRACETAM; ETONOGESTREL; GABAPENTIN; LAMOTRIGINE; MEDROXYPROGESTERONE ACETATE; MESTRANOL PLUS NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; PROGESTERONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

CONDOM; CONTRACEPTION; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; ENZYME INDUCTION; EPILEPSY; FEMALE; HORMONE METABOLISM; HUMAN; OVULATION; PREGNANCY; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK FACTOR;

ANTICONVULSANTS; CHOICE BEHAVIOR; CONTRACEPTION BEHAVIOR; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVES, ORAL, HORMONAL; CONTRACEPTIVES, POSTCOITAL, HORMONAL; DESOGESTREL; DRUG INTERACTIONS; ENZYME INDUCTION; EPILEPSY; FEMALE; HUMANS; INTRAUTERINE DEVICES; LIVER; MEDROXYPROGESTERONE 17-ACETATE;

EID: 33748712107     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2006.00671.x     Document Type: Review

References (11)

1. Garnett WR. Clinical pharmacology of topiramate: a review. Epilepsia 2000;41(suppl 1):61-5.
2. Sabers A, Ohman I, Tomson T. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsia 2002;43:47.
3. Clinical Effectiveness Unit of the Faculty of Family Planning and Reproductive Health. Changes to prescribing information for lamotrigine. 2005. Available at http://www.ffprhc.org.uk/admin/uploads/831 lamotrigine.pdf.
4. Faculty of Family Planning and Reproductive Health. Drug interactions with hormonal contraception. J Fam Plann Reprod Health Care 2005 ;31:139-51.
5. Guillebaud J. Drug interactions with hormonal contraception. J Fam Plann Reprod Health Care 2005;31:335-6.
6. Clinical Effectiveness Unit of the Faculty of Family Planning and Reproductive Health. Use of contraception outside terms of the product licence. J Fam Plann Reprod Health Care 2005;31:225-42.
7. Clinical Effectiveness Unit of the Faculty of Family Planning and Reproductive Health. Levonelle 1500 mg and the use of liver enzyme inducing drugs. Available at http://www.ffprhc.org.uk/ admin/uploads/534 Levonelle1500KeyStatement.pdf.
8. Pfizer Ltd. Depo-Provera, summary of product characteristics. 2004.
9. Gupta C, Osterman J, Santen R, et al. In vivo metabolism of progestins. J Clin Endocrinol Metab 1979;48:816-20.
10. Faculty of Family Planning and Reproductive Health. Statement on Medicines and Healthcare Products Regulatory Agency Guidance on DMPA: November 18, 2004.Available at http://www.ffprhc.org.uk/admin/uploads/Depo Provera alert statement.pdf.
11. Bounds W, Guillebaud J. Observational series on women using contraceptive Mirena concurrently with anti-epileptic and other enzyme-inducing drugs. J Fam Plann Reprod Health Care 2002;28:78-80.